Glucocorticoids enhance interleukin-4 production to neo-antigen (hyaluronidase) in children immunocompromised with cytostatic drugs

Pediatr Allergy Immunol. 2002 Oct;13(5):375-80. doi: 10.1034/j.1399-3038.2002.02039.x.

Abstract

Immunoglobulin E (IgE)-mediated immediate-type allergic reactions to hyaluronidase have been observed in children with central nervous system (CNS) tumors. Glucocorticoids, used as therapy for brain edema, are discussed controversially as T helper 2 (Th2) stimulatory factors. In this study we investigated the role of glucocorticoids on a Th2 cytokine-promoting effect in children with CNS tumors. Peripheral blood mononuclear cells (PBMCs) from: 29 children suffering from malignant brain tumors, of whom 23 received short-term glucocorticoid treatment (for 3-4 days) during the course of chemotherapy; 18 children with nephrotic syndrome or renal transplantation receiving long-term glucocorticoid treatment; and 13 healthy children, were incubated with phytohemagglutinin (PHA) and/or anti-CD28 monoclonal antibody (mAb) and, in a second approach, with hyaluronidase. The concentrations of Th cell-mediated cytokines - interleukin (IL)-4, IL-10, and interferon-gamma (IFN-gamma) - were measured in supernatants. The IL-4 production of PBMCs incubated with PHA/anti-CD28 mAb from children with repeated co-administration of glucocorticoids, hyaluronidase, and cytostatic drugs (median: 249.9 pg/ml; range: 234.4-261.7) was significantly higher (p < 0.0001) than IL-4 production of PBMC from children of all the other groups (median: 86.18; range: 16.0-212.5). There was no significant difference in the levels of IL-10 and IFN-gamma within the groups. PBMCs stimulated only with hyaluronidase failed to produce detectable levels of cytokines. The results of this study indicate that repeated co-administration of glucocorticoids and hyaluronidase (a neo-antigen) enhance IL-4 production in vitro and thus may induce the production of specific IgE antibodies in children immunocompromised with cytostatic drugs. Hyaluronidase itself does not stimulate in vitro IL-4 synthesis in PBMCs of children receiving cytostatic drugs.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Antineoplastic Agents / immunology
  • Antineoplastic Agents / therapeutic use*
  • Antineoplastic Combined Chemotherapy Protocols / immunology
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Central Nervous System Neoplasms / drug therapy
  • Central Nervous System Neoplasms / immunology
  • Child
  • Child Welfare
  • Child, Preschool
  • Cytokines / biosynthesis*
  • Cytokines / drug effects*
  • Cytokines / immunology
  • Dexamethasone / immunology
  • Dexamethasone / therapeutic use*
  • Dose-Response Relationship, Drug
  • Drug Therapy, Combination
  • Female
  • Glucocorticoids / immunology
  • Glucocorticoids / therapeutic use*
  • HLA-D Antigens / drug effects
  • HLA-D Antigens / immunology
  • Humans
  • Hyaluronoglucosaminidase / immunology
  • Hyaluronoglucosaminidase / therapeutic use*
  • Immunocompromised Host / drug effects*
  • Immunocompromised Host / immunology
  • Infant
  • Infant Welfare
  • Interferon-gamma / biosynthesis
  • Interferon-gamma / drug effects
  • Interferon-gamma / immunology
  • Interleukin-10 / biosynthesis
  • Interleukin-10 / immunology
  • Interleukin-4 / biosynthesis
  • Interleukin-4 / immunology
  • Leukocytes, Mononuclear / drug effects
  • Leukocytes, Mononuclear / metabolism
  • Male
  • Treatment Outcome

Substances

  • Antineoplastic Agents
  • Cytokines
  • Glucocorticoids
  • HLA-D Antigens
  • Interleukin-10
  • Interleukin-4
  • Dexamethasone
  • Interferon-gamma
  • Hyaluronoglucosaminidase